Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Barbara Gitlitz, MD

    TitleAssociate Professor of Clinical Medicine
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressNOR 3440
    Health Sciences Campus
    Los Angeles California 90089-9173
    Phone+1 323 865 3906
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      After graduating from the State University of New York Stony Brook campus, Dr. Gitlitz moved out west to California. After completing a fellowship in Hematology Oncology and Translational Investigation at UCLA, she stayed on as an Assistant Professor. Much of her early clinical-translational work involved cancer immunotherapy including one of the first trials of a Dendritic Cell Vaccine for patients with kidney cancer. She then joined the Keck School of Medicine of USC as an Associate Professor to spearhead the USC oncology effort in lung cancer and head and neck cancer. Her most rewarding part of working at USC is being a member of multidisciplinary treatment teams; where medical oncologists, surgeons, radiation oncologists and other specialists can collaborate together on the best, individualized treatment plan for a patient. Her dedicated, compassionate clinical care has been noticed by the community as she has been consistently nominated to the list of Los Angeles Magazine Super Doctors, Pasadena Magazine Top Doctors, and US News Top Doctors.

      She has received research grants from the American Cancer Society, the National Institute of Health and STOP cancer. Currently she is a member of the Stand Up 2 Cancer Epigenetics Dream Team where she will bring novel trials to treat cancer with combinations of immunotherapy and therapy to awaken important genes that are “turned off†by growing cancers. Dr. Gitlitz has a passion for working with scientists seeking ways to personalize therapy and bring novel drugs (clinical trials) to treat her patients. She believes that each person’s cancer may have unique molecular/genomic features to help guide the best treatment plan. Dr. Gitlitz is an accomplished author and has numerous articles published in peer reviewed cancer journals and she has written numerous book chapters. She has been invited to lecture at cancer conferences all across the United States and internationally.


      Collapse Biography 
      Collapse Clinical Trials
      Collapse Awards and Honors
      USC Norris Comprehensive Cancer Center2004 - 2009Stop Cancer Award
      STOP Cancer2013David L. Ray Memorial Seed Grant

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Ou SI, Lee TK, Young L, Fernandez-Rocha MY, Pavlick D, Schrock AB, Zhu VW, Milliken J, Ali SM, Gitlitz B. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer. 2017 Apr; 106:110-114. PMID: 28285684.
        View in: PubMed
      2. Ou SI, Schrock AB, Bocharov EV, Klempner SJ, Haddad CK, Steinecker G, Johnson M, Gitlitz B, Chung J, Campregher PV, Ross JS, Stephens PJ, Miller VA, Suh JH, Ali SM, Velcheti V. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. J Thorac Oncol. 2016 Nov 27. PMID: 27903463.
        View in: PubMed
      3. Gitlitz B, Addario B, Sable-Hunt A, Novello S, Vavala T, Chen R, Bittoni M, Park SL, Jennings M, Oxnard G. PD1.05 (also presented as P1.49): The Genomics of Young Emergent Lung Cancer. J Thorac Oncol. 2016 Oct; 11(10S):S174. PMID: 27676481.
        View in: PubMed
      4. Gitlitz B, Addario B, Sable-Hunt A, Novello S, Vavala T, Chen R, Bittoni M, Park SL, Jennings M, Oxnard G. P1.49 (also presented as PD1.05): The Genomics of Young Emergent Lung Cancer: Track: Advanced NSCLC. J Thorac Oncol. 2016 Oct; 11(10S):S214. PMID: 27676536.
        View in: PubMed
      5. Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz B, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov. 2016 Jun; 6(6):601-11. PMID: 27102076.
        View in: PubMed
      6. Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9. PMID: 26802155.
        View in: PubMed
      7. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-118.e2. PMID: 26498504.
        View in: PubMed
      8. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 1; 21(19):4321-6. PMID: 26106072.
        View in: PubMed
      9. Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer. 2015 May; 88(2):231-4. PMID: 25736571.
        View in: PubMed
      10. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz B, Mack PC, Gandara DR. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. PMID: 25490004.
        View in: PubMed
      11. Piatek CI, Raja GL, Ji L, Gitlitz B, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. PMID: 25374407.
        View in: PubMed
      12. Thara E, Gitlitz B. Eribulin: a new-generation antimicrotubule agent in lung cancer therapy. Future Oncol. 2014 Oct; 10(12):1913-24. PMID: 25386810.
        View in: PubMed
      13. Gitlitz B, Bernstein E, Santos ES, Otterson GA, Milne G, Syto M, Burrows F, Zaknoen S. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4):577-82. PMID: 24736085.
        View in: PubMed
      14. Hughes B, Mileshkin L, Townley P, Gitlitz B, Eaton K, Mitchell P, Hicks R, Wood K, Amler L, Fine BM, Loecke D, Pirzkall A. Pertuzumab and Erlotinib in Patients With Relapsed Non-Small Cell Lung Cancer: A Phase II Study Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging. Oncologist. 2014; 19(2):175-6. PMID: 24457379.
        View in: PubMed
      15. Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014 Feb; 24(2):232-40. PMID: 23721245.
        View in: PubMed
      16. Liu SV, Fabbri M, Gitlitz B, Laird-Offringa IA. Epigenetic therapy in lung cancer. Front Oncol. 2013; 3:135. PMID: 23755372.
        View in: PubMed
      17. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz B, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80. PMID: 22831987.
        View in: PubMed
      18. Gitlitz B, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8. PMID: 22198425.
        View in: PubMed
      19. Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol. 2012 Mar; 7(3):579-86. PMID: 22198426.
        View in: PubMed
      20. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz B, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 2012 Feb 15; 18(4):1092-100. PMID: 22179664.
        View in: PubMed
      21. Chao J, Synold TW, Morgan RJ, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz B, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. PMID: 22105720.
        View in: PubMed
      22. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. PMID: 21716143.
        View in: PubMed
      23. Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2012 Apr; 23(4):1023-9. PMID: 21778300.
        View in: PubMed
      24. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz B, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res. 2011 May 15; 17(10):3304-15. PMID: 21364032.
        View in: PubMed
      25. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz B, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. PMID: 20142723.
        View in: PubMed
      26. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. PMID: 21273177.
        View in: PubMed
      27. Gitlitz B, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, Schulz TK, Sundaram PK, Ho C, Gandara DR. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010 Nov; 5(11):1835-40. PMID: 20881645.
        View in: PubMed
      28. Reckamp K, Gitlitz B, Chen LC, Patel R, Milne G, Syto M, Jezior D, Zaknoen S. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer. 2011 Feb 15; 117(4):809-18. PMID: 20922800.
        View in: PubMed
      29. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jun 20; 28(18):3076-83. PMID: 20479403.
        View in: PubMed
      30. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, Belani CP. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 1; 28(1):56-62. PMID: 19933908.
        View in: PubMed
      31. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009 Jan; 4(1):97-101. PMID: 19096314.
        View in: PubMed
      32. Garland L, Gitlitz B, Ebbinghaus S, Pan H, de Haan H, Puri RK, Von Hoff D, Figlin R. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother. 2005 Jul-Aug; 28(4):376-81. PMID: 16000956.
        View in: PubMed
      33. Suh RD, Goldin JG, Wallace AB, Sheehan RE, Heinze SB, Gitlitz B, Figlin RA. Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment. Radiology. 2004 May; 231(2):359-64. PMID: 15128982.
        View in: PubMed
      34. Pantuck AJ, van Ophoven A, Gitlitz B, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother. 2004 May-Jun; 27(3):240-53. PMID: 15076142.
        View in: PubMed
      35. Gitlitz B, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, Sanchez JD, Shapiro RM, Figlin RA. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003 Nov 1; 98(9):1863-9. PMID: 14584068.
        View in: PubMed
      36. Kiertscher SM, Gitlitz B, Figlin RA, Roth MD. Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients. Int J Cancer. 2003 Nov 1; 107(2):256-61. PMID: 12949803.
        View in: PubMed
      37. Gitlitz B, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003 Sep-Oct; 26(5):412-9. PMID: 12973030.
        View in: PubMed
      38. Gitlitz B, Figlin RA. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am. 2003 Aug; 30(3):589-600. PMID: 12953757.
        View in: PubMed
      39. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003 Jun 15; 97(12):2995-3002. PMID: 12784334.
        View in: PubMed
      40. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Figlin RA, Belldegrun AS. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003 Jun; 169(6):2076-83. PMID: 12771723.
        View in: PubMed
      41. Gitlitz B, Figlin RA, Kiertscher SM, Moldawer N, Rosen F, Roth MD. Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer. J Immunother. 2003 Mar-Apr; 26(2):171-8. PMID: 12616109.
        View in: PubMed
      42. Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz B, deKernion JB, Figlin RA, Belldegrun AS. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003 Mar; 169(3):909-16. PMID: 12576811.
        View in: PubMed
      43. Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz B, Figlin RA, Belldegrun AS. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003 Feb; 61(2):314-9. PMID: 12597937.
        View in: PubMed
      44. Gitlitz B, Figlin RA. Cell, gene and vaccine based strategies in kidney cancer. Cancer Treat Res. 2003; 116:183-98. PMID: 14650833.
        View in: PubMed
      45. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz B, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002 Mar 1; 20(5):1368-74. PMID: 11870181.
        View in: PubMed
      46. Chao D, Zisman A, Pantuck AJ, Gitlitz B, Freedland SJ, Said JW, Figlin RA, Belldegrun AS. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol. 2002 Jan; 167(1):71-4. PMID: 11743278.
        View in: PubMed
      47. Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res. 2001 Nov 1; 61(21):7925-33. PMID: 11691814.
        View in: PubMed
      48. Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz B, de Kernion JB, Figlin RA, Belldegrun AS. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol. 2001 Jul; 166(1):54-8. PMID: 11435822.
        View in: PubMed
      49. Gitlitz B, Belldegrun AS, Figlin RA. Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol. 2001 May; 19(2):141-7. PMID: 11354534.
        View in: PubMed
      50. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz B, deKernion JB, Figlin RA, Belldegrun AS. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001 Mar 15; 19(6):1649-57. PMID: 11250993.
        View in: PubMed
      51. Gitlitz B, Hoffman DM, Moldawer N, Belldegrun A, Figlin RA. Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. Cancer J. 2001 Mar-Apr; 7(2):112-20. PMID: 11324764.
        View in: PubMed
      52. Gitlitz B, Figlin RA, Pantuck AJ, Belldegrun AS. Dendritic cell-based immunotherapy of renal cell carcinoma. Curr Urol Rep. 2001 Feb; 2(1):46-52. PMID: 12084295.
        View in: PubMed
      53. Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 2000 Jul-Aug; 6(4):220-33. PMID: 11038142.
        View in: PubMed
      54. Roth MD, Gitlitz B, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, Figlin RA. Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res. 2000 Apr 1; 60(7):1934-41. PMID: 10766183.
        View in: PubMed
      55. Hoffman DM, Gitlitz B, Belldegrun A, Figlin RA. Adoptive cellular therapy. Semin Oncol. 2000 Apr; 27(2):221-33. PMID: 10768601.
        View in: PubMed
      56. Hinkel A, Tso CL, Gitlitz B, Neagos N, Schmid I, Paik SH, deKernion J, Figlin R, Belldegrun A. Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma. J Immunother. 2000 Jan; 23(1):83-93. PMID: 10687141.
        View in: PubMed
      57. Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res. 1999 Feb; 5(2):445-54. PMID: 10037196.
        View in: PubMed
      58. Mulders P, Tso CL, Pang S, Kaboo R, McBride WH, Hinkel A, Gitlitz B, Dannull J, Figlin R, Belldegrun A. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. J Immunother. 1998 May; 21(3):170-80. PMID: 9610908.
        View in: PubMed
      59. Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, deKernion J, Belldegrun A. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S92-7. PMID: 9457402.
        View in: PubMed
      60. Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, deKernion J, Belldegrun A. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol. 1997 Sep; 158(3 Pt 1):740-5. PMID: 9258071.
        View in: PubMed
      61. Gitlitz B, Kuehne E. Caring for children in foster care. J Pediatr Health Care. 1997 May-Jun; 11(3):127-9. PMID: 9197627.
        View in: PubMed
      62. Gitlitz B, Belldegrun A, Figlin RA. Immunotherapy and gene therapy. Semin Urol Oncol. 1996 Nov; 14(4):237-43. PMID: 8946624.
        View in: PubMed
      63. Franklin JR, Figlin R, Rauch J, Gitlitz B, Belldegrun A. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol. 1996 Nov; 14(4):230-6. PMID: 8946623.
        View in: PubMed
      64. Figlin RA, Gitlitz B, Belldegrun A. Immunologic approaches to the treatment of cancer. Cancer Invest. 1995; 13(3):339-40. PMID: 7743386.
        View in: PubMed
      65. Gitlitz B. Early ambulation following lower extremity amputation. Rocky Mt Med J. 1968 Jul; 65(7):49-52. PMID: 5667702.
        View in: PubMed
      66. GITLITZ B. THE PARATHYROID CYST. REVIEW OF LITERATURE AND CASE REPORT. Rocky Mt Med J. 1965 Jul; 62:38-41. PMID: 14299236.
        View in: PubMed
      67. GITLITZ B. What price security? Rocky Mt Med J. 1960 Nov; 57:55-61. PMID: 13705779.
        View in: PubMed
      68. GITLITZ B, KUNKEL RE. Multiple foreign body ingestion. Rocky Mt Med J. 1955 Jul; 52(7):629-31. PMID: 14396228.
        View in: PubMed